About
IL-1 Inhibitor
Areas of Focus
Categories
Small Molecule Pharmaceutical
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
35
By Phase
PHASE2: 1PHASE1/PHASE2: 1
By Status
RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06634875Lead Sponsor
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
PHASE2Recruiting
20 participants
Started: Jan 30, 2025 · Completed: Dec 31, 2026
NCT04121442Lead Sponsor
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
PHASE1/PHASE2Completed
15 participants
Started: Sep 1, 2020 · Completed: Jul 15, 2024
Locations (1)
Headquarters
Stockholm, Sweden
Map
Loading map...